Literature DB >> 21056589

Zinc pre-treatment enhances NMDAR-mediated excitotoxicity in cultured cortical neurons from SOD1(G93A) mouse, a model of amyotrophic lateral sclerosis.

Michele Nutini1, Valerio Frazzini, Claudia Marini, Alida Spalloni, Stefano L Sensi, Patrizia Longone.   

Abstract

Zn²+ is co-released at glutamatergic synapses throughout the central nervous system and acts as a neuromodulator for glutamatergic neurotransmission, as a key modulator of NMDA receptor functioning. Zn²+ is also implicated in the neurotoxicity associated with several models of acute brain injury and neurodegeneration. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motor neurons in the spinal cord and cortex. In this study, we have investigated the modulatory role exerted by Zn²+ in NMDA-mediated neurotoxicity in either near-pure or mixed cortical cultured neurons obtained from either mice over-expressing the G93A mutant form of Cu/Zn superoxide dismutase (SOD1) human gene, a gene linked to familial ALS, or wild type (WT) mice. To that aim, SOD1(G93A) or WT cultures were exposed to either NMDA by itself or to Zn²+ prior to a toxic challenge with NMDA, and neuronal loss evaluated 24 h later. While we failed to observe any significant difference between NMDA and Zn²+/NMDA-mediated toxicity in mixed SOD1(G93A) or WT cortical cultures, different vulnerability to these toxic paradigms was found in near-pure neuronal cultures. In the WT near-pure neuronal cultures, a brief exposure to sublethal concentrations of Zn²+-enhanced NMDA receptor-mediated cell death, an effect that was far more pronounced in the SOD1(G93A) cultures. This increased excitotoxicity in SOD1(G93A) near-pure neuronal cultures appears to be mediated by a significant increase in NMDA-dependent rises of intraneuronal Ca²+ levels as well as enhanced production of cytosolic reactive oxygen species, while the injurious process seems to be unrelated to activation of nNOS or ERK1/2 pathways. This article is part of a Special Issue entitled 'Trends in neuropharmacology: in memory of Erminio Costa'.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056589     DOI: 10.1016/j.neuropharm.2010.11.001

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement.

Authors:  Hatasu Kobayashi; Koji Abe; Tohru Matsuura; Yoshio Ikeda; Toshiaki Hitomi; Yuji Akechi; Toshiyuki Habu; Wanyang Liu; Hiroko Okuda; Akio Koizumi
Journal:  Am J Hum Genet       Date:  2011-06-16       Impact factor: 11.025

Review 2.  Exposure to environmental toxicants and pathogenesis of amyotrophic lateral sclerosis: state of the art and research perspectives.

Authors:  Francesca Trojsi; Maria Rosaria Monsurrò; Gioacchino Tedeschi
Journal:  Int J Mol Sci       Date:  2013-07-24       Impact factor: 5.923

3.  Seeking homeostasis: temporal trends in respiration, oxidation, and calcium in SOD1 G93A Amyotrophic Lateral Sclerosis mice.

Authors:  Cameron W Irvin; Renaid B Kim; Cassie S Mitchell
Journal:  Front Cell Neurosci       Date:  2015-07-01       Impact factor: 5.505

Review 4.  State of the field: An informatics-based systematic review of the SOD1-G93A amyotrophic lateral sclerosis transgenic mouse model.

Authors:  Renaid B Kim; Cameron W Irvin; Keval R Tilva; Cassie S Mitchell
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2015-05-22       Impact factor: 4.092

5.  Early life metal dysregulation in amyotrophic lateral sclerosis.

Authors:  Claudia Figueroa-Romero; Kristen A Mikhail; Chris Gennings; Paul Curtin; Ghalib A Bello; Tatiana M Botero; Stephen A Goutman; Eva L Feldman; Manish Arora; Christine Austin
Journal:  Ann Clin Transl Neurol       Date:  2020-05-21       Impact factor: 4.511

6.  Clinical and Electrophysiological Hints to TMS in De Novo Patients with Parkinson's Disease and Progressive Supranuclear Palsy.

Authors:  Francesco Fisicaro; Giuseppe Lanza; Mariagiovanna Cantone; Raffaele Ferri; Giovanni Pennisi; Alessandra Nicoletti; Mario Zappia; Rita Bella; Manuela Pennisi
Journal:  J Pers Med       Date:  2020-12-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.